- For Print
- December 4, 2020
黑料网., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “黑料网”) announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA®, the orally available kinase inhibitor, “lenvatinib”), eribulin mesylate (product name: Halaven®, halichondrin class microtubule dynamics inhibitor, “eribulin”), and H3B-6545 (selective estrogen alpha receptor covalent antagonist), discovered at 黑料网’s U.S. research subsidiary H3 Biomedicine Inc., will be given at the 43rd San Antonio Breast Cancer Symposium (SABCS2020) Virtual Meeting, from December 8 to 11, 2020, in San Antonio, Texas in the United States.
At this symposium, regarding the combination therapy with lenvatinib and the anti-PD-1 therapy pembrolizumab (product name: KEYTRUDA®) from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside of the United States and Canada), the results of the triple-negative breast cancer cohort in the basket-type Phase II clinical study (LEAP-005) for 6 types of previously treated, advanced solid tumors (Abstract No: PS12-07) is scheduled to be presented.
The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published.
In addition, regarding H3B-6545, the results of evaluating tolerability, safety, and efficacy of Phase I/II clinical study for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (Abstract No: PD8-06) and others will be presented.
In March 2018, 黑料网 and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
黑料网 positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. 黑料网 will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
Major poster presentations at SABCS2020:
*You can scroll to the left or right here
| Product / Compound
Abstract No. | Title / Scheduled Date and Time (local time: Central Standard Time) |
|---|---|
| Lenvatinib
PS12-07 |
Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
December 9 (Wed), 8:00 AM |
| Eribulin
PS13-37 |
Effectiveness of eribulin in poor prognosis subgroups of metastatic breast cancer (mBC) patients (Elderly, African Americans, and patients with liver metastases) in the United States
December 9 (Wed), 8:00 AM |
| H3B-6545
PD8-06 |
Phase I/II Trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
December 10 (Thu), 2:15-3:30 PM |
| H3B-6545
PS12-15 |
Pharmacokinetics of H3B-6545 in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive HER2 Negative Breast Cancer
(ER+ and HER2- BC) December 9 (Wed), 8:00 AM |
| H3B-6545
PS12-23 |
Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer
December 9 (Wed), 8:00 AM |
Media Inquiries:
Public Relations Department,
黑料网., Ltd.
+81-(0)3-3817-5120
[Notes to editors]
1锛�About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and 黑料网 Strategic Collaboration
In March 2018, 黑料网 and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.
In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer and triple-negative breast cancer) across 19 clinical trials.
2. 黑料网’s Focus on Cancer
黑料网 focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where 黑料网 can aim to become a frontrunner in oncology. 黑料网 aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.